SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Pfizer - Quaterly Results

31 Jan 2025 Evaluate
Revenue reduced marginally to stand at Rs. 5379.90 millions during the quarter ended December 2024. The figure stood at Rs. 5399.70 millions during the year-ago period.The Company's Net profit for the December 2024 quarter have declined marginally to Rs. 1276.00  millions as against Rs. 1299.80 millions reported during the corresponding quarter ended.OP of the company witnessed a marginal growth to 1887.50 millions from 1884.00 millions in the same quarter last year.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202412 202312 % Var 202412 202312 % Var 202403 202303 % Var
Sales 5379.90 5399.70 -0.37 16894.40 16465.40 2.61 21931.70 24247.60 -9.55
Other Income 427.60 358.50 19.27 1276.70 1053.80 21.15 1805.10 1010.50 78.63
PBIDT 1887.50 1884.00 0.19 6404.00 5512.50 16.17 8158.10 9099.10 -10.34
Interest 15.10 28.60 -47.20 57.20 84.60 -32.39 154.10 133.90 15.09
PBDT 1872.40 1934.90 -3.23 6346.80 5507.40 15.24 8083.50 9295.20 -13.04
Depreciation 148.00 175.50 -15.67 443.90 485.30 -8.53 622.80 1055.10 -40.97
PBT 1724.40 1759.40 -1.99 5902.90 5022.10 17.54 7460.70 8240.10 -9.46
TAX 448.40 459.60 -2.44 1536.30 1297.40 18.41 1947.40 2000.80 -2.67
Deferred Tax -52.60 167.90 -131.33 -114.10 198.00 -157.63 361.10 -519.10 -169.56
PAT 1276.00 1299.80 -1.83 4366.60 3724.70 17.23 5513.30 6239.30 -11.64
Equity 457.50 457.50 0.00 457.50 457.50 0.00 457.50 457.50 0.00
PBIDTM(%) 35.08 34.89 0.55 37.91 33.48 13.22 37.20 37.53 -0.87

Pfizer Share Price

4811.05 61.45 (1.29%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×